Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Br J Haematol. 2021 May 24;193(6):1142–1150. doi: 10.1111/bjh.17534

Figure 1.

Figure 1.

A. Men with MDS/MPN-U (P=0.021) and CMML (P=0.007) have lower platelets compared to women at diagnosis. B. Men have higher R-IPSS at diagnosis (P=0.021) across different MDS/MPN sub-types. C. Men have worse overall survival compared to women (P=0.011) in the entire cohort of patients with MDS/MPN neoplasms. D. Men have worse overall survival compared to women (P=0.040) in the high-risk MDS/MPN cohort including patients with MDS/MPN-U, CMML and aCML.